Valuation: Abivax

Capitalization 8.31B 9.73B 7.61B 7.2B 13.32B 931B 13.39B 90.62B 35.28B 442B 36.5B 35.73B 1,535B P/E ratio 2026 *
-29.4x
P/E ratio 2027 * -30.1x
Enterprise value 7.75B 9.08B 7.1B 6.71B 12.43B 869B 12.5B 84.58B 32.93B 412B 34.06B 33.35B 1,433B EV / Sales 2026 *
3,005x
EV / Sales 2027 * 66.2x
Free-Float
97.41%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week-4.81%
Current month+8.76%
1 month+0.10%
3 months-1.22%
6 months+17.34%
Current year-12.87%
1 week 101.5
Extreme 101.5
108.5
1 month 92.05
Extreme 92.05
111.2
Current year 87.5
Extreme 87.5
132
1 year 5
Extreme 5
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
Manager TitleAgeSince
Chief Executive Officer 68 04/05/2023
Director of Finance/CFO - 01/01/2017
Chief Tech/Sci/R&D Officer - 18/03/2026
Director TitleAgeSince
Chairman - 15/08/2022
Chairman 68 04/05/2023
Director/Board Member 60 10/07/2023
Change 5d. change 1-year change 3-years change Capi.($)
+1.16%-4.81%+1,807.27%+474.48% 9.73B
-0.82%-3.93%-17.36%-17.47% 42.33B
+0.47%+1.03%+40.86%+32.80% 35.19B
+2.90%-0.75%+275.32%+479.59% 31.88B
-1.53%-2.32%+14.40%-8.40% 28.77B
-1.45%-2.16%+28.40%+24.87% 26.78B
+2.50%+3.26% - - 15.13B
+3.68%-0.98%+232.53%+4,188.18% 13.51B
+2.33%+0.98%+138.55%+118.53% 12.82B
-0.64%-1.97%+6.67%-1.97% 12.12B
Average +0.86%-1.54%+280.74%+587.85% 22.83B
Weighted average by Cap. +0.49%-1.76%+155.93%+369.82%

Financials

2026 *2027 *
Net sales 2.58M 3.02M 2.36M 2.23M 4.14M 289M 4.16M 28.14M 10.96M 137M 11.33M 11.1M 477M 118M 138M 108M 102M 189M 13.21B 190M 1.29B 501M 6.27B 518M 507M 21.79B
Net income -274M -321M -251M -237M -439M -30.69B -442M -2.99B -1.16B -14.56B -1.2B -1.18B -50.62B -189M -221M -173M -164M -303M -21.17B -305M -2.06B -802M -10.05B -830M -812M -34.91B
Net Debt -554M -649M -508M -480M -889M -62.13B -894M -6.05B -2.35B -29.48B -2.44B -2.38B -102B -502M -588M -460M -435M -806M -56.28B -810M -5.48B -2.13B -26.71B -2.21B -2.16B -92.84B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
69
Date Price Change Volume
13/05/26 104.90 +1.16% 89,914
12/05/26 103.70 -0.38% 114,134
11/05/26 104.10 -1.33% 111,516
08/05/26 105.50 -2.04% 107,360
07/05/26 107.70 -2.27% 139,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
104.90EUR
Average target price
121.48EUR
Spread / Average Target
+15.81%

Quarterly revenue - Rate of surprise